The Changes in Epidemiology of Imipenem-Resistant Acinetobacter baumannii Bacteremia in a Pediatric Intensive Care Unit for 17 Years

Dongsub Kim,1,2,* Haejeong Lee,1, Joon-sik Choi,4 Christina M. Croney,5 Ki-Sup Park,6,7 Hyo Jung Park,8 Joongbum Cho,9 Sohee Son,1
Jin Yeong Kim,10 Soo-Han Choi,11 Hee Jae Huh,12 Kwan Soo Ko,13 Nam Yong Lee,12 and Yae-Jean Kim1,14

1Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
2Department of Pediatrics, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
3Department of Pediatrics, Severance Children’s Hospital, Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea
4Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
5Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA
6Samkwang Medical Laboratories Genetree, Seoul, Korea
7Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea
8Department of Pharmaceutical Services, Samsung Medical Center, Seoul, Korea
9Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
10Samsung Biomedical Research Institute, Seoul, Korea
11Department of Pediatrics, Pusan National University Hospital, School of Medicine, Pusan National University, Busan, Korea
12Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
13Department of Microbiology, Sungkyunkwan University School of Medicine, Seoul, Korea
14Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Seoul, Korea

ABSTRACT

Background: Acinetobacter baumannii infections cause high morbidity and mortality in intensive care unit (ICU) patients. However, there are limited data on the changes of long-term epidemiology of imipenem resistance in A. baumannii bacteremia among pediatric ICU (PICU) patients.

Methods: A retrospective review was performed on patients with A. baumannii bacteremia in PICU of a tertiary teaching hospital from 2000 to 2016. Antimicrobial susceptibility tests, multilocus sequence typing (MLST), and polymerase chain reaction for antimicrobial resistance genes were performed for available isolates.

Results: A. baumannii bacteremia occurred in 27 patients; imipenem-sensitive A. baumannii (ISAB, n = 10, 37%) and imipenem-resistant A. baumannii (IRAB, n = 17, 63%). There was a clear shift in the antibiogram of A. baumannii during the study period. From 2000 to 2003, all isolates were ISAB (n = 6). From 2005 to 2008, both IRAB (n = 5) and ISAB (n = 4) were isolated. However, from 2009, all isolates were IRAB (n = 12). Ten isolates were available for additional test and confirmed as IRAB. MLST analysis showed that among 10 isolates, sequence type...
138 was predominant (n = 7). All 10 isolates were positive for OXA-23-like and OXA-51-like carbapenemase. Of 27 bacteremia patients, 11 were male (41%), the median age at bacteremia onset was 5.2 years (range, 0–18.6 years). In 33% (9/27) of patients, A. baumannii was isolated from tracheal aspirate prior to development of bacteremia (median, 8 days; range, 5–124 days). The overall case-fatality rate was 63% (17/27) within 28 days. There was no statistical difference in the case fatality rate between ISAB and IRAB groups (50% vs. 71%; \(P = 0.422\)).

**Conclusion:** IRAB bacteremia causes serious threat in patients in PICU. Proactive infection control measures and antimicrobial stewardship are crucial for managing IRAB infection in PICU.

**Keywords:** Pediatric Intensive Care Units; Acinetobacter baumannii; Bacteremia

## INTRODUCTION

Improved medical care and invasive procedures for high-risk pediatric intensive care unit (PICU) patients have led to a longer duration of survival and prolonged hospitalization. However, prolonged hospitalization results in a higher probability of healthcare-associated infection. Common bacterial pathogens in pediatric healthcare-associated infection are *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, coagulase negative staphylococci, *Escherichia coli*, and *Acinetobacter* spp.\(^1\)–\(^3\)

*Acinetobacter baumannii* is an aerobic, Gram-negative bacterium associated with high morbidity and mortality in clinical settings. *A. baumannii* infection may lead to high health-care costs and prolonged hospitalization. The most common clinical manifestations are ventilator-associated pneumonia and bacteremia.\(^4\) Furthermore, the imipenem resistance rate of *A. baumannii* species is increasing worldwide.\(^5\),\(^6\)

However, there are limited data on long-term epidemiology of *A. baumannii* bacteremia among PICU patients.\(^7\)–\(^9\) In this study, we analyzed the epidemiology of bacteremia caused by *A. baumannii* infection in PICU patients and molecular analysis of isolated bacteria.

## METHODS

### Collection of patient’s information

A retrospective chart review was performed on pediatric patients < 19 years old who developed bacteremia caused by *A. baumannii* from January 2000 to December 2016 in the PICU at Samsung Medical Center, Seoul, South Korea. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) biotyper was not used during the study period. Clinical information and microbiological data were collected from all patients.

### Bacterial isolates and species identification

*A. baumannii* were detected among patients with bloodstream infections in the PICU from January 2000 to December 2016. Only the first isolate from each patient was included in this study. Initially, isolates that were identified as *Acinetobacter* species by the VITEK 2 system (bioMérieux, Marcy l’Etoile, France) from clinical care were included. All of *A. baumannii* were differentiated to imipenem-sensitive *A. baumannii* (ISAB) and imipenem-resistant *A. baumannii* (IRAB).
From January 2010 to December 2016, \textit{A. baumannii} were collected and species-level identification using partial \textit{rpoB} gene sequences were performed,\textsuperscript{10,11} and were tested for antimicrobial susceptibility.

\textbf{Antimicrobial susceptibility testing}

Antimicrobial susceptibility was confirmed for available isolates using the broth microdilution method following the Clinical and Laboratory Standards Institute (CLSI) guidelines.\textsuperscript{12} The minimum inhibitory concentrations (MICs) of 12 antimicrobial agents, including imipenem, meropenem, cefotaxime, cefepime, ceftazidime, amikacin, ciprofloxacin, tetracycline, piperacillin-tazobactam, colistin, polymyxin B, and tigecycline were determined. Susceptibility was defined according to CLSI breakpoints,\textsuperscript{12} using \textit{Escherichia coli} ATCC 25922 and \textit{Pseudomonas aeruginosa} ATCC 27853 as controls. All tests were performed in duplicate, and each test included three biological replicates per strain.

\textbf{Multilocus sequence typing (MLST) and antimicrobial resistance genes}

MLST was performed for \textit{A. baumannii} isolates as previously described.\textsuperscript{13} All MLST data were submitted to the \textit{A. baumannii} MLST database and Oxford scheme was applied.\textsuperscript{14,15} Clonal complexes were determined using the eBURST program.\textsuperscript{16} For all of the IRAB isolates, resistance genes, including \textit{bla}\textsubscript{IMP}, \textit{bla}\textsubscript{VIM}, \textit{bla}\textsubscript{GIM}, \textit{bla}\textsubscript{SIM}, \textit{bla}\textsubscript{KPC}, \textit{bla}\textsubscript{NDM-1}, \textit{bla}\textsubscript{OXA-48}, \textit{bla}\textsubscript{OXA-23-like}, \textit{bla}\textsubscript{OXA-24-like}, \textit{bla}\textsubscript{OXA-51-like}, and \textit{bla}\textsubscript{OXA-58-like} were detected by polymerase chain reaction, as described previously.\textsuperscript{17}

\textbf{Statistical analysis}

Fisher’s exact test was used to analyze categorical variables. A \textit{P} value of < 0.05 was considered statistically significant. Overall survival rates were estimated using the Kaplan-Meier method, and differences in survival curves were compared using the log-rank test by GraphPad Prism version 9.3.1 (GraphPad Software, San Diego, CA, USA).

\textbf{Ethics statement}

The Institutional Review Board (IRB) at Samsung Medical Center, Seoul, South Korea, reviewed and approved this study (approval number: 2020-05-020-002). Informed consent was exempted by IRB.

\section*{RESULTS}

\textbf{Patient characteristics and epidemiology}

Bacteremia episodes occurred in 27 patients; ISAB (\textit{n} = 10) and IRAB (\textit{n} = 17). Male patients were 41\% (11/27), and the median age at the onset of bacteremia was 5.2 years (range, 0–18.6 years). Among the underlying conditions in patients with \textit{A. baumannii} bacteremia, hematology-oncology disease was the most common underlying condition (14/27, 52\%) followed by neurological diseases (4/27, 15\%) (Table 1).

In 33\% (9/27, ISAB = 3/10, IRAB = 6/17) of patients, \textit{A. baumannii} was isolated from tracheal aspirate prior to the development of bacteremia with a median duration of 8 days (range, 5–124).

\textbf{Epidemiological changes in imipenem susceptibility and antimicrobial resistance pattern}

There was a clear shift in the antibiogram of \textit{A. baumannii} during the study period. From 2000 to

\url{https://jkms.org}
2003, all *A. baumannii* isolates were ISAB (n = 6). From 2005 to 2008, both IRAB (n = 5) and ISAB (n = 4) were isolated. However, from 2009, all *A. baumannii* isolates were IRAB (n = 12) (Fig. 1).

In 2011, an outbreak of IRAB occurred causing six patients with IRAB bacteremia (patient number 20–25).

Among 27 *A. baumannii* bacteremia episodes, 10 isolates were available. All 10 isolates were resistant to imipenem and meropenem. They were also all resistant to amikacin and ciprofloxacin. Five isolates were sensitive to tetracycline, and three were sensitive to tigecycline. All of the isolates were sensitive to colistin with MIC ≤ 2 mg/L and polymyxin B with MIC ≤ 1 mg/L by microdilution methods (Table 2).

| Parameters                        | All (N = 27) | ISAB (n = 10) | IRAB (n = 17) |
|-----------------------------------|--------------|---------------|---------------|
| Median age, yr                    | 5.2          | 1.9 (range, 0.6–16) | 5.4 (0–18.6) |
| Male                              | 11           | 5             | 6             |
| Median ICU stay prior to bacteremia, day | 5           | 5 (range, 0–51)  | 4 (0–48)     |
| Underlying disease                |              |               |               |
| Hematology and oncology           | 14           | 2             | 12            |
| HCT                               | 8            | 0             | 8             |
| Cardiology*                       | 3            | 2             | 1             |
| Pulmonology                       | 2            | 1             | 1             |
| Neurology                         | 4            | 3             | 1             |
| Others*                           | 3            | 2             | 1             |
| No underlying disease             | 1            | 1             | 0             |

ISAB = imipenem-sensitive *A. baumannii*, IRAB = imipenem-resistant *A. baumannii*, ICU = intensive care unit, HCT = hematopoietic cell transplantation.

*There was one neonate under 28 days with congenital heart disease was included.

*Primary immunodeficiency, renal disease, vascular malformation.

---

2003, all *A. baumannii* isolates were ISAB (n = 6). From 2005 to 2008, both IRAB (n = 5) and ISAB (n = 4) were isolated. However, from 2009, all *A. baumannii* isolates were IRAB (n = 12) (Fig. 1).

In 2011, an outbreak of IRAB occurred causing six patients with IRAB bacteremia (patient number 20–25).

Among 27 *A. baumannii* bacteremia episodes, 10 isolates were available. All 10 isolates were resistant to imipenem and meropenem. They were also all resistant to amikacin and ciprofloxacin. Five isolates were sensitive to tetracycline, and three were sensitive to tigecycline. All of the isolates were sensitive to colistin with MIC ≤ 2 mg/L and polymyxin B with MIC ≤ 1 mg/L by microdilution methods (Table 2).

| Parameters                        | All (N = 27) | ISAB (n = 10) | IRAB (n = 17) |
|-----------------------------------|--------------|---------------|---------------|
| Median age, yr                    | 5.2          | 1.9 (range, 0.6–16) | 5.4 (0–18.6) |
| Male                              | 11           | 5             | 6             |
| Median ICU stay prior to bacteremia, day | 5           | 5 (range, 0–51)  | 4 (0–48)     |
| Underlying disease                |              |               |               |
| Hematology and oncology           | 14           | 2             | 12            |
| HCT                               | 8            | 0             | 8             |
| Cardiology*                       | 3            | 2             | 1             |
| Pulmonology                       | 2            | 1             | 1             |
| Neurology                         | 4            | 3             | 1             |
| Others*                           | 3            | 2             | 1             |
| No underlying disease             | 1            | 1             | 0             |

ISAB = imipenem-sensitive *A. baumannii*, IRAB = imipenem-resistant *A. baumannii*, ICU = intensive care unit, HCT = hematopoietic cell transplantation.

*There was one neonate under 28 days with congenital heart disease was included.

*Primary immunodeficiency, renal disease, vascular malformation.

---

2003, all *A. baumannii* isolates were ISAB (n = 6). From 2005 to 2008, both IRAB (n = 5) and ISAB (n = 4) were isolated. However, from 2009, all *A. baumannii* isolates were IRAB (n = 12) (Fig. 1).

In 2011, an outbreak of IRAB occurred causing six patients with IRAB bacteremia (patient number 20–25).

Among 27 *A. baumannii* bacteremia episodes, 10 isolates were available. All 10 isolates were resistant to imipenem and meropenem. They were also all resistant to amikacin and ciprofloxacin. Five isolates were sensitive to tetracycline, and three were sensitive to tigecycline. All of the isolates were sensitive to colistin with MIC ≤ 2 mg/L and polymyxin B with MIC ≤ 1 mg/L by microdilution methods (Table 2).
MLST and antimicrobial resistance genes

Among the 10 isolates tested for molecular analysis, nine were isolated from 2010 to 2012 (Table 3). During that period, seven of them were sequence type (ST) 138 and two isolates from patients who were transferred from outside hospitals, were ST75 and ST92.

Following the 2011 outbreak, there were no A. baumannii bacteremia cases from 2013 to 2015. An IRAB isolate with ST191 was identified in 2016 in a patient transferred from outside hospital and this was not progressed to additional outbreak in the PICU.

Among the resistance genes tested (\(\text{bla}\)OXA-24-like, \(\text{bla}\)OXA-51-like, \(\text{bla}\)OXA-54-like, \(\text{bla}\)IMP, \(\text{bla}\)VIM, \(\text{bla}\)NDM, \(\text{bla}\)KPC, \(\text{bla}\)SIM, \(\text{bla}\)SPM, and \(\text{bla}\)OXA-48), carbapenemase Ambler class A and B genes were not detected. All ten isolates were positive to class D genes (OXA-23 like and OXA-51 like) and negative to OXA-24-like and OXA-54-like genes (Table 3).

Treatment outcome

Overall, among the 27 patients (ISAB: \(n = 10\), IRAB: \(n = 17\)), the case-fatality rate within 28 days from bacteremia was 63% (17/27). There was no statistical difference in the fatality rate between the ISAB and IRAB groups (5/10, 50% vs. 12/17, 71%; \(P = 0.422\)). In Kaplan-Meier survival curve, no significant difference between the two groups was observed (Fig. 2). However, the case fatality rate of hematology-oncology patients was higher than that of rest of other patients (86% vs. 38%, \(P = 0.011\)).

Table 2. Antimicrobial susceptibility profiles of A. baumannii isolates

| Isolate | MIC, mg/L (antimicrobial susceptibility category) |
|---------|-----------------------------------------------|
|         | IMI | MRP | CTX | CFP | CAZ | AMK | CIP | TET | P/T | CL | PB | TIG |
| Ab10-18 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 16 (R) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |
| Ab10-19 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 4 (S) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |
| Ab11-20 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 8 (I) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |
| Ab11-22 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 4 (S) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |
| Ab11-23 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 4 (S) | > 256/4 (R) | 1 (S) | 1 (S) | 2 (S) |
| Ab11-24 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 16 (R) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |
| Ab11-25 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 4 (S) | > 256/4 (R) | 1 (S) | 1 (S) | 2 (S) |
| Ab12-26 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 8 (I) | > 256/4 (R) | 2 (S) | 1 (S) | 2 (S) |
| Ab16-27 | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | > 64 (R) | > 128 (R) | > 64 (R) | 4 (S) | > 256/4 (R) | 1 (S) | 1 (S) | 4 (I) |

MIC = minimum inhibitory concentration, IMI = imipenem, MRP = meropenem, CTX = ceftotaxime, CFP = cefepime, CAZ = ceftazidime, AMK = amikacin, CIP = ciprofloxacin, TET = tetracycline, P/T = piperacillin-tazobactam, CL = colistin, PB = polymyxin B, TIG = tigecycline, R = resistant, I = intermediate-resistant, S = susceptible, Ab16-27 = A. baumannii isolated year-patient number.

Table 3. Genotypes of A. baumannii and identification of OXA-type carbapenemase genes

| Isolate No. | Year | CC | ST | OXA-23-like | OXA-24-like | OXA-51-like | OXA-58-like |
|-------------|------|----|----|-------------|-------------|-------------|-------------|
| Ab10-18     | 2010 | CC92 | ST138 | + | - | + | - |
| Ab10-19     | 2010 | CC92 | ST75 | + | - | + | - |
| Ab11-20     | 2011 | CC92 | ST138 | + | - | + | - |
| Ab11-21     | 2011 | CC92 | ST138 | + | - | + | - |
| Ab11-22     | 2011 | CC92 | ST138 | + | - | + | - |
| Ab11-23     | 2011 | CC92 | ST138 | + | - | + | - |
| Ab11-24     | 2011 | CC92 | ST138 | + | - | + | - |
| Ab11-25     | 2011 | CC92 | ST92 | + | - | + | - |
| Ab12-26     | 2012 | CC92 | ST138 | + | - | + | - |
| Ab16-27     | 2016 | CC92 | ST191 | + | - | + | - |

All of the A. baumannii isolates were negative to \(\text{bla}\)OXY, \(\text{bla}\)CAZ, \(\text{bla}\)BLA, \(\text{bla}\)IMP, \(\text{bla}\)VIM, \(\text{bla}\)KPC, \(\text{bla}\)SIM, \(\text{bla}\)SPM, and \(\text{bla}\)OXA. CC = clonal complex, ST = sequence type, Ab16-27 = A. baumannii isolated year-patient number.

*These patients were transferred from outside hospital.
The median interval from *A. baumannii* bacteremia onset to death was two days (range, 0–13) in ISAB and it was also two days in IRAB (range, 0–9) group. When IRAB group was examined further in detail, 35% (6/17) of patients with IRAB bacteremia died within 2 days before the culture and susceptibility test results became available and 67% (4/6) of patients had previous positive culture for IRAB from the tracheal aspirate before bacteremia developed.

A total of 78% (21/27) of all the patients were treated with susceptible antibiotics within 2 days from bacteremia onset, 62% (13/21) of patients died. In ISAB group, six patients (6/10) were treated with carbapenem and 33% (2/6) died. Whereas four patients (4/10) were treated without carbapenem and 75% (3/4) died ($P = 0.519$). In IRAB group, seven patients (7/17, 41%) were treated with colistin and 71% (5/7) died. Ten patients (10/17, 59%) in IRAB group did not receive colistin and 70% (7/10) died ($P = 0.949$).

**Infection control**

With an alert on IRAB outbreak in 2011, environmental culture including the hands of medical workers, computers and telephones of the nursing station, sink, and all of 15 bed rails was performed in 2011–2012. Reeducation of contact precaution and hand hygiene were performed to PICU medical workers. IRAB isolation frequency was dramatically decreased after infection control intervention. Antibiotic stewardship was strengthened.

**DISCUSSION**

This was a study on the long-term epidemiology of *A. baumannii* bacteremia and antibiotic resistance in PICU for 17 consecutive years of pre-MALDI-TOF period. We observed a dramatic shift in antibiotic susceptibility from all ISAB before 2004 to all IRAB in 2009 that was followed by an outbreak with high mortality due to ST138 IRAB. This outbreak peaked in 2011 and was controlled after an extensive infection control intervention.

Resistance to the carbapenem is a global issue. In the United States, the rate of *A. baumannii* resistance to imipenem and meropenem in 2008 was reported as 48% and 57.4% respectively. In Korea, the rate of *A. baumannii* resistance to carbapenem among adult patients was 85% in 2015. Imipenem resistance among pediatric patients is also increasing. In other study of
Korean PICU and neonatal intensive care unit (ICU) of Taiwan, the rapid emergence of IRAB was also observed.\(^\text{9,21}\) Cases of colistin-resistant AB were reported among patients who were treated with colistin to treat carbapenem-resistant \textit{A. baumannii} (CRAB) infection.\(^\text{22}\)

We observed that all isolates were positive for OXA-23 like and clonal complex 92. OXA-23 like \(\beta\)-lactamase is a main carbapenase of \textit{A. baumannii}.\(^\text{23,24}\) Clonal complex 92 is a widely distributed clone and major cause of \textit{A. baumannii} outbreaks worldwide.\(^\text{25}\) It is also a major clone in Korean CRAB.\(^\text{26}\) The distribution of sequence type and resistant gene change according to year of isolation with ST191 predominance was observed among isolated \textit{A. baumannii} in Korean tertiary hospitals.\(^\text{23,27}\)

In this study, 35\% (6/17) of patients with IRAB bacteremia died within 2 days before the culture and susceptibility test results became available. Among the six patients, 67\% (4/6) had previous positive culture for IRAB from the tracheal aspirate before bacteremia onset. Active surveillance for preceding tracheal colonization or pneumonia and proactive antibiotic treatment strategy may allow the early initiation of appropriate antibiotic treatment in high risk rapidly deteriorating patients.\(^\text{28}\)

In the ICU, the early identification and prevention of an outbreak are important. The infection control team consisting of healthcare personnel expertise is important.\(^\text{29}\) In a study of Korean adults in ICU, active surveillance and cohorting of patients for the CRAB infected or colonized patients reduced CRAB infection.\(^\text{30}\) In this study, infection control efforts in PICU were sustained to prevent additional outbreak. As a result, there was not a single case of \textit{A. baumannii} bacteremia (both ISAB and IRAB) for three years (2013–2015). When we have there was one IRAB bacteremia patient transferred from an outside hospital in 2016, this was not progressed to outbreak due to strict infection control measures (Fig. 1). Multifaceted infection control approaches including timely feedback, regular education and revisiting of control measures among infection control team, pediatric infectious disease experts, critical care physicians, and nursing staffs are essential.

This study has some limitations. Although the study period was relatively long (17 years), this was a retrospective study, and not all bacterial isolates were tested. Therefore, MLST or bacterial resistance analysis could not be performed on isolates from the early period. In addition, the source of the outbreak was not clear.

In conclusion, this was a long-term epidemiology study that evaluated IRAB bacteremia in PICU patients. Antimicrobial stewardship programs and multifaceted infection control approaches are essential to reduce outbreak caused by a resistant pathogen such as IRAB in high-risk PICU patients.

**REFERENCES**

1. Lakshmi KS, Jayashree M, Singhi S, Ray P. Study of nosocomial primary bloodstream infections in a pediatric intensive care unit. \textit{J Trop Pediatr} 2007;53(2):87-92.
2. Le NK, Hf W, Vu PD, Khu DT, Le HT, Hoang BT, et al. High prevalence of hospital-acquired infections caused by Gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: a multi-centre point prevalence survey. \textit{Medicine (Baltimore)} 2016;95(27):e4099.
3. Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011-2014. *Infect Control Hosp Epidemiol* 2018;39(1):1-11.

4. Vila J, Bonomo RA. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. *Future Microbiol* 2007;2(1):9-12.

5. Endo S, Yano H, Hirakata Y, Araik K, Kanamori H, Ogawa M, et al. Molecular epidemiology of carbapenem-non-susceptible *Acinetobacter baumannii* in Japan. *J Antimicrob Chemother* 2012;67(7):1623-6.

6. Evans BA, Amyes SG. OXA β-lactamases. *Clin Microbiol Rev* 2014;27(2):241-63.

7. Lee HY, Hsu SY, Hsu JF, Chen CL, Wang YH, Chiu CH. Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteremia in neonates. *J Microbiol Immunol Infect* 2018;51(3):367-76.

8. Sultan AM, Seliem WA. Identifying risk factors for healthcare-associated infections caused by carbapenem-resistant *Acinetobacter baumannii* in a neonatal intensive care unit. *Sultan Qaboos Univ Med J* 2018;18(1):e75-80.

9. Hong KB, Oh HS, Song JS, Lim JH, Kang DK, Son IS, et al. Investigation and control of an outbreak of imipenem-resistant *Acinetobacter baumannii* infection in a pediatric intensive care unit. *Pediatr Infect Dis J* 2012;31(7):685-90.

10. La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the *rpoB* gene and flanking spacers for molecular identification of *Acinetobacter* species. *Clin Microbiol Infect* 2007;13(1):48-54.

11. Feil EJ, Smith JM, Enright MC, Spratt BG. Estimating recombinational parameters in *Streptococcus pneumoniae* from multilocus sequence typing data. *Genetics* 2000;154(4):1439-50.

12. Park YK, Jung SI, Park KH, Lee H, Jung DS, et al. Two distinct clones of carbapenem-resistant *Acinetobacter baumannii* isolates from Korean hospitals. *Diagn Microbiol Infect Dis* 2009;64(4):389-95.

13. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). *Diagn Microbiol Infect Dis* 2009;65(4):414-26.

14. Kim D, Ahn JY, Lee CH, Jang SI, Lee H, Yong D, et al. Changes in antimicrobial susceptibility and major clones of *Acinetobacter calcoaceticus-baumannii* complex isolates from a single hospital in Korea over 7 years. *J Med Microbiol* 2012;61(Pt 1):71-9.
21. Thatrimontrichai A,Apisarnthanarak A,Chanvitan P,Janjindamai W,Dissaneevate S,Maneenil G. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study. *Pediatr Infect Dis J* 2013;32(2):140-5. [PUBMED] [CROSSREF]

22. Garcia Casallas JC,Robayo-Amortegui H,Corrêdo-Rozo Z,Carrasco-Marquez AM,Escobar-Perez J. Bacteremia by colistin-resistant *Acinetobacter baumannii* isolate: a case report. *J Med Case Reports* 2019;13(1):141. [PUBMED] [CROSSREF]

23. Jeon H,Kim S,Kim MH,Kim SY,Nam D,Park SC,et al. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates from a Korean hospital that carry blaOXA-23. *Infect Genet Evol* 2018;58:232-6. [PUBMED] [CROSSREF]

24. Smith CA,Antunes NT,Stewart NK,Toth M,Kumarasiri M,Chang M,et al. Structural basis for carbapenemase activity of the OXA-23 β-lactamase from *Acinetobacter baumannii*. *Chem Biol* 2013;20(9):1107-15. [PUBMED] [CROSSREF]

25. Karah N,Sundsfjord A,Towner K,Samuelsen Ø. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. *Drug Resist Updat* 2012;15(4):237-47. [PUBMED] [CROSSREF]

26. Kim DH,Jung SI,Kwon KT,Ko KS. Occurrence of diverse AbGRI1-type genomic islands in *Acinetobacter baumannii* global clone 2 isolates from South Korea. *Antimicrob Agents Chemother* 2017;61(2):e01972-16. [PUBMED] [CROSSREF]

27. Kim MH,Jeong H,Sim YM,Lee S,Yong D,Ryu CM,et al. Using comparative genomics to understand molecular features of carbapenem-resistant *Acinetobacter baumannii* from South Korea causing invasive infections and their clinical implications. *PLoS One* 2020;15(2):e0229416. [PUBMED] [CROSSREF]

28. Lampati L,Maggioni E,Langer M,Malacarne P,Mozzo R,Pesenti A,et al. Can routine surveillance samples from tracheal aspirate predict bacterial flora in cases of ventilator-associated pneumonia? *Minerva Anestesiol* 2009;75(10):555-62. [PUBMED]

29. Karageorgopoulos DE,Falagas ME. Current control and treatment of multidrug-resistant *Acinetobacter baumannii* infections. *Lancet Infect Dis* 2008;8(12):751-62. [PUBMED] [CROSSREF]

30. An JH,Kim YH,Moon JE,Jeong JH,Kim SH,Kang SJ,et al. Active surveillance for carbapenem-resistant *Acinetobacter baumannii* in a medical intensive care unit: can it predict and reduce subsequent infections and the use of colistin? *Am J Infect Control* 2017;45(6):667-72. [PUBMED] [CROSSREF]